If a client has a 2D6 enzyme deficiency, how will their drug metabolism be affected?

A deficiency in the 2D6 enzyme indicates that the patient has reduced ability to metabolize certain drugs that are processed by this enzyme. The CYP2D6 enzyme is responsible for the metabolism of a wide range of medications, including many commonly prescribed drugs such as some antidepressants, antipsychotics, and beta-blockers. When this enzyme is deficient, the metabolic pathways that would typically convert these drugs into their active or inactive forms are impaired.

As a result, drugs that would normally be metabolized quickly in individuals with normal enzyme activity will instead be metabolized slowly in someone with 2D6 deficiency. This slower metabolism can lead to increased drug levels in the body, potentially causing enhanced pharmacological effects or adverse reactions. The slower conversion of drugs to metabolites means they remain in the system longer than intended, which can influence dosing and therapeutic outcomes.

Understanding this pharmacogenetic aspect is crucial for tailoring medication regimens to prevent toxicity and ensure efficacy in clients with 2D6 enzyme deficiencies. Thus, the answer that indicates the drug will be metabolized slowly accurately reflects the impact of the enzyme's deficiency on drug metabolism.